查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600446

抗体药物复合体市场：按作用机制、药物、技术、适应症和最终用户 - 2025-2030 年全球预测

Antibody Drug Conjugate Market by Mechanism of Action (CD30 Antibodies, ErbB2 Antibodies), Drugs (Adcetris, Blenrep, Enhertu), Technology, Indication, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

抗体药物复合体市场2023年估值为56亿美元，预计2024年将达到64.8亿美元，复合年增长率为16.12%，预计到2030年将达到159.6亿美元。

抗体药物复合体(ADC) 是靶向癌症治疗的一种前沿方法，它利用单株抗体的特异性将细胞毒性药物直接递送至癌细胞，从而最大限度地减少和减少全身暴露。对ADC的需求在于它们能够透过精确靶向癌细胞来提高治疗指数，与传统化疗相比具有显着优势。 ADC 主要应用于肿瘤学，但也正在考虑在自体免疫感染疾病中的应用。最终用途广泛，包括医院、专门的癌症治疗中心和研究机构。癌症发生率的增加、生物共轭技术的进步以及研发投资的增加推动了市场的成长。关键的成长要素还包括临床试验中不断增长的 ADC 管道以及对肿瘤生物学的更好理解。使用新颖机制和改进的连接器技术来开发 ADC 来提高稳定性和功效存在重大机会。 ADC 在非肿瘤领域也有扩大使用的潜力。然而，高开发成本、复杂的製造流程和监管障碍等挑战是主要限制。该市场还面临来自CAR-T细胞疗法等替代疗法的竞争。创新可以集中在增强有效载荷多样性、提高瞄准精度和减少脱靶效应。研究 ADC 和免疫查核点抑制剂的联合治疗是另一种研究途径。 ADC 市场的特点是技术快速进步和合作联盟，凸显了个人化医疗的趋势。公司应优先考虑策略联盟和许可协议，以利用生物製药的进步。总体而言，将 ADC 的治疗适用性扩展到肿瘤学之外并完善其递送机制对于市场的持续成长至关重要，并确保 ADC 始终处于精准医疗创新的前沿。

主要市场统计
基准年[2023] 56亿美元
预测年份 [2024] 64.8亿美元
预测年份 [2030] 159.6亿美元
复合年增长率（%） 16.12%

市场动态：快速发展的抗体药物复合体市场的关键市场洞察

抗体药物复合体市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 全球癌症发生率增加
    • 临床试验活动的成长和强大的产品平臺
    • 鼓励癌症研究的政府支持与倡议
  • 市场限制因素
    • ADC 製造成本上升和产品召回
  • 市场机会
    • 加大生物製药研发投入并推出新型ADC
    • 采用先进技术进行ADC开发
  • 市场挑战
    • ADC 製造复杂性

波特五力：驾驭抗体药物复合体市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗体药物复合体市场的外部影响

外部宏观环境因素在塑造抗体药物复合体市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解抗体药物复合体市场的竞争格局

抗体药物复合体市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵抗体药物复合体市场供应商的绩效评估

FPNV定位矩阵是评估抗体药物复合体市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球癌症发生率增加
      • 临床试验活动的成长和强大的产品平臺
      • 政府对癌症研究的支持与努力
    • 抑制因素
      • 高 ADC 製造成本和产品召回
    • 机会
      • 加大生物製药研发投入并推出新型ADC
      • 采用先进技术进行ADC开发
    • 任务
      • ADC 製造复杂性
  • 市场区隔分析
    • 作用机转：提高ErbB2抗体（HER2）有效治疗乳癌和胃癌的优越性
    • 製药：Enhertz 作为一种有前景的肿瘤标靶治疗药物的渗透
    • 技术：优先采用无连结器技术来简化製造流程并提高 ADC 稳定性
    • 适应症：快速使用ADC有效治疗乳癌
    • 最终用户：学术研究机构新开发的ADC新用途
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依作用机转分類的抗体药物复合体市场

  • CD30抗体
  • ErbB2抗体

第七章按药物抗体药物复合体市场

  • ADCETRIS
  • 布伦代表
  • 恩赫图
  • 门头
  • 帕多切夫
  • 特罗德维

第八章抗体药物复合体市场：依技术分类

  • 可切割接头
  • 没有连结
  • 不可切割的接头

第九章按适应症分類的抗体药物复合体市场

  • 血癌
  • 乳癌
  • 淋巴瘤
  • 多发性骨髓瘤
  • 尿路上皮癌和膀胱癌

第10章抗体药物复合体市场：依最终用户分类

  • 学术研究所
  • 生物製药和生物技术公司
  • 医院
  • 专门癌症中心

第十一章美洲抗体药物复合体市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太抗体药物复合体市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲抗体药物复合体市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Lonza 加强抗体药物复合体的商业供给能力
    • CHMP 建议欧盟批准 ENHERTU 用于核准HER2 突变的晚期非小细胞肺癌患者
    • Pixis Oncology 完成对 Apexigen 的收购
    • 百济神与 DualityBio 宣布合作推进固态肿瘤差异化抗体药物复合体(ADC) 疗法
    • 诺华支持的 Tagworks 筹集了 6500 万美元 A 轮融资，以进一步开发 ADC 点击发布技术
    • Lonza 收购 Synafix 以加强抗体药物复合体产品
    • SONY与Astellas来签署联合研究协议，探索癌症领域新的 ADC 平台
    • BioNTech 与 DualityBio 建立全球战略伙伴关係关係，加速固态肿瘤差异化抗体药物复合体疗法的开发
    • 辉瑞投资430亿美元对抗癌症
    • Astra Zeneca与 KYM Biosciences 签署 CMG901、claudin 18.2抗体药物复合体授权合约
    • 美国FDA核准Trodelvy 用于治疗先前接受过治疗的 HR+/HER2- 转移性乳癌患者

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • ADC Therapeutics SA
  • Ambrx Biopharma Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Byondis BV
  • Celldex Therapeutics Inc.
  • Creative Biolabs, Inc.
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Heidelberg Pharma AG
  • ImmunoGen, Inc.
  • Innate Pharma SA
  • Innovent Biologics, Inc.
  • Lonza Group Ltd.
  • MacroGenics, Inc.
  • MediLink Therapeutics
  • Merck KGaA
  • Mersana Therapeutics, Inc.
  • Novartis AG
  • Oxford Biotherapeutics Limited
  • Pfizer, Inc.
  • Pheon Therapeutics Ltd.
  • Piramal Pharma Limited
  • Recipharm AB
  • Sanofi SA
  • Sorrento Therapeutics, Inc.
  • Tagworks Pharmaceuticals BV
  • Takeda Pharmaceutical Company Limited
  • Tubulis GmbH
  • Zymeworks Inc.
Product Code: MRR-657F2A76F4DB

The Antibody Drug Conjugate Market was valued at USD 5.60 billion in 2023, expected to reach USD 6.48 billion in 2024, and is projected to grow at a CAGR of 16.12%, to USD 15.96 billion by 2030.

Antibody Drug Conjugates (ADCs) represent a cutting-edge approach in targeted cancer therapy, leveraging the specificity of monoclonal antibodies to deliver cytotoxic agents directly to cancer cells, thus minimizing systemic exposure and reducing side effects. The necessity of ADCs lies in their ability to enhance the therapeutic index by precisely targeting cancer cells, providing a substantial advantage over traditional chemotherapy. ADCs find application predominantly in oncology, but potential uses in autoimmune and infectious diseases are under exploration. The end-use scope spans hospitals, specialized cancer treatment centers, and research institutes. Market growth is driven by increased cancer prevalence, advancements in bioconjugation technologies, and rising investments in R&D. Key growth factors also include a growing pipeline of ADCs in clinical trials and a better understanding of tumor biology. Notable opportunities exist in developing ADCs with novel mechanisms and improved linker technologies to enhance stability and efficacy. There is also potential for expanding the use of ADCs in non-oncological fields. However, challenges such as high developmental costs, complex manufacturing processes, and regulatory hurdles pose significant limitations. The market also faces competition from alternative therapies like CAR-T cell therapy. Innovations can focus on enhancing payload diversity, improving targeting accuracy, and reducing off-target effects. Exploring ADC combinations with immune checkpoint inhibitors offers another research avenue. The ADC market is characterized by rapid technological advancements and collaborative partnerships, emphasizing a trend towards personalized medicine. Companies should prioritize strategic collaborations and licensing agreements to leverage biopharmaceutical advancements. Overall, expanding the therapeutic applicability of ADCs beyond oncology and refining the delivery mechanisms are vital for sustained market growth, ensuring ADCs remain at the forefront of precision medicine innovations.

KEY MARKET STATISTICS
Base Year [2023] USD 5.60 billion
Estimated Year [2024] USD 6.48 billion
Forecast Year [2030] USD 15.96 billion
CAGR (%) 16.12%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibody Drug Conjugate Market

The Antibody Drug Conjugate Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cancer worldwide
    • Growth in clinical trial activities and robust product pipeline
    • Government support and initiatives encouraging research on cancer
  • Market Restraints
    • High manufacturing cost of ADC and incidences of product recalls
  • Market Opportunities
    • Increasing investment in biopharma R&D and introduction of novel ADCs
    • Adoption of advanced technologies for developing ADC
  • Market Challenges
    • Complexity in manufacturing of ADCs

Porter's Five Forces: A Strategic Tool for Navigating the Antibody Drug Conjugate Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibody Drug Conjugate Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibody Drug Conjugate Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibody Drug Conjugate Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibody Drug Conjugate Market

A detailed market share analysis in the Antibody Drug Conjugate Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibody Drug Conjugate Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibody Drug Conjugate Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Antibody Drug Conjugate Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., ADC Therapeutics SA, Ambrx Biopharma Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BioNTech SE, Bristol-Myers Squibb Company, Byondis B.V., Celldex Therapeutics Inc., Creative Biolabs, Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Heidelberg Pharma AG, ImmunoGen, Inc., Innate Pharma SA, Innovent Biologics, Inc., Lonza Group Ltd., MacroGenics, Inc., MediLink Therapeutics, Merck KGaA, Mersana Therapeutics, Inc., Novartis AG, Oxford Biotherapeutics Limited, Pfizer, Inc., Pheon Therapeutics Ltd., Piramal Pharma Limited, Recipharm AB, Sanofi S.A., Sorrento Therapeutics, Inc., Tagworks Pharmaceuticals BV, Takeda Pharmaceutical Company Limited, Tubulis GmbH, and Zymeworks Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Drug Conjugate Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Mechanism of Action, market is studied across CD30 Antibodies and ErbB2 Antibodies.
  • Based on Drugs, market is studied across Adcetris, Blenrep, Enhertu, Kadcyla, Padcev, and Trodelvy.
  • Based on Technology, market is studied across Cleavable Linker, Linkerless, and Non-Cleavable Linker.
  • Based on Indication, market is studied across Blood Cancer, Breast Cancer, Lymphoma, Multiple Myeloma, and Urothelial Cancer & Bladder Cancer.
  • Based on End User, market is studied across Academic Research Institutes, Biopharmaceutical & Biotechnology Companies, Hospitals, and Specialized Cancer Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across Alaska, California, Florida, Illinois, Massachusetts, Michigan, Montana, Nevada, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer worldwide
      • 5.1.1.2. Growth in clinical trial activities and robust product pipeline
      • 5.1.1.3. Government support and initiatives encouraging research on cancer
    • 5.1.2. Restraints
      • 5.1.2.1. High manufacturing cost of ADC and incidences of product recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investment in biopharma R&D and introduction of novel ADCs
      • 5.1.3.2. Adoption of advanced technologies for developing ADC
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in manufacturing of ADCs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Mechanism of Action: Increasing preference for ErbB2 antibodies (HER2) for effective treatment of breast and gastric cancer
    • 5.2.2. Drugs: Penetration of Enhertu as a promising drug for targeted therapies in the oncology field
    • 5.2.3. Technology: Preference for linkerless technology for simplifying the manufacturing process and improving the stability of ADCs
    • 5.2.4. Indication: Rapid usage of ADCs for efficient treatment of breast cancer
    • 5.2.5. End User: Emerging use of ADCs by academic research institutes for novel developments
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antibody Drug Conjugate Market, by Mechanism of Action

  • 6.1. Introduction
  • 6.2. CD30 Antibodies
  • 6.3. ErbB2 Antibodies

7. Antibody Drug Conjugate Market, by Drugs

  • 7.1. Introduction
  • 7.2. Adcetris
  • 7.3. Blenrep
  • 7.4. Enhertu
  • 7.5. Kadcyla
  • 7.6. Padcev
  • 7.7. Trodelvy

8. Antibody Drug Conjugate Market, by Technology

  • 8.1. Introduction
  • 8.2. Cleavable Linker
  • 8.3. Linkerless
  • 8.4. Non-Cleavable Linker

9. Antibody Drug Conjugate Market, by Indication

  • 9.1. Introduction
  • 9.2. Blood Cancer
  • 9.3. Breast Cancer
  • 9.4. Lymphoma
  • 9.5. Multiple Myeloma
  • 9.6. Urothelial Cancer & Bladder Cancer

10. Antibody Drug Conjugate Market, by End User

  • 10.1. Introduction
  • 10.2. Academic Research Institutes
  • 10.3. Biopharmaceutical & Biotechnology Companies
  • 10.4. Hospitals
  • 10.5. Specialized Cancer Centers

11. Americas Antibody Drug Conjugate Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Antibody Drug Conjugate Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Antibody Drug Conjugate Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Lonza to enhance commercial antibody-drug conjugate supply capacity
    • 14.3.2. ENHERTU Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer
    • 14.3.3. Pyxis Oncology Successfully Completes Acquisition of Apexigen
    • 14.3.4. BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
    • 14.3.5. Novartis-Backed Tagworks Raises USD 65 Million Series A to Further ADC, Click-to-Release Tech
    • 14.3.6. Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
    • 14.3.7. Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field
    • 14.3.8. BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
    • 14.3.9. Pfizer Invests USD 43 Billion to Battle Cancer
    • 14.3.10. AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate
    • 14.3.11. U.S. FDA Approves Trodelvy in Pre-treated HR+/HER2- Metastatic Breast Cancer

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. ADC Therapeutics SA
  • 4. Ambrx Biopharma Inc.
  • 5. Amgen Inc.
  • 6. Astellas Pharma Inc.
  • 7. AstraZeneca PLC
  • 8. Bayer AG
  • 9. BioNTech SE
  • 10. Bristol-Myers Squibb Company
  • 11. Byondis B.V.
  • 12. Celldex Therapeutics Inc.
  • 13. Creative Biolabs, Inc.
  • 14. Daiichi Sankyo Company, Limited
  • 15. Eisai Co., Ltd.
  • 16. F. Hoffmann-La Roche Ltd.
  • 17. Gilead Sciences, Inc.
  • 18. GlaxoSmithKline PLC
  • 19. Heidelberg Pharma AG
  • 20. ImmunoGen, Inc.
  • 21. Innate Pharma SA
  • 22. Innovent Biologics, Inc.
  • 23. Lonza Group Ltd.
  • 24. MacroGenics, Inc.
  • 25. MediLink Therapeutics
  • 26. Merck KGaA
  • 27. Mersana Therapeutics, Inc.
  • 28. Novartis AG
  • 29. Oxford Biotherapeutics Limited
  • 30. Pfizer, Inc.
  • 31. Pheon Therapeutics Ltd.
  • 32. Piramal Pharma Limited
  • 33. Recipharm AB
  • 34. Sanofi S.A.
  • 35. Sorrento Therapeutics, Inc.
  • 36. Tagworks Pharmaceuticals BV
  • 37. Takeda Pharmaceutical Company Limited
  • 38. Tubulis GmbH
  • 39. Zymeworks Inc.

LIST OF FIGURES

  • FIGURE 1. ANTIBODY DRUG CONJUGATE MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY DRUG CONJUGATE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANTIBODY DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANTIBODY DRUG CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODY DRUG CONJUGATE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBODY DRUG CONJUGATE MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD30 ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ERBB2 ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ADCETRIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLENREP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ENHERTU, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY KADCYLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PADCEV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TRODELVY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE LINKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKERLESS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON-CLEAVABLE LINKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY UROTHELIAL CANCER & BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. ANTIBODY DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 242. ANTIBODY DRUG CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2023